• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Profile and compliance of recipients of injection depot medroxy progesterone acetate as a contraceptive method in the government tertiary care hospital in Mandya, South Karnataka, India
【24h】

Profile and compliance of recipients of injection depot medroxy progesterone acetate as a contraceptive method in the government tertiary care hospital in Mandya, South Karnataka, India

机译：注射仓麦克风孕酮接受者的概况和依从性醋酸盐作为南卡纳塔克邦南卡纳塔卡的政府高等护理医院的避孕方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The advanced contraceptive devices available nowadays have minimal side effects and utmost efficacy. The use of safe and effective contraception is the need of the hour in India. Inj. Depot medroxy progesterone (DMPA) has been found to provide effective, long acting and reversible contraception in lactating mother and post-abortal patients. Objective of this study was to describe the profile of women utilizing inj. DMPA as a contraceptive, to determine its compliance and to assess the factors affecting discontinuation of inj. DMPA (Anthara) at the government tertiary care institute in Mandya. Methods: The present study was a record-based study of 18 months (January 2018 to June 2019). The records of 266 women who utilized inj. DMPA as contraception in our institution was analysed. Results: It was observed that out of 266 women 48.5% were from age group of 21-25 years and 64.3% were primipara. Most of the women who initiated inj. DMPA (Anthara) were in the lactational period (56.0%). Most common side effect was irregular bleeding (54.8%). Discontinuation rate was 55.6% after first injection and 16.9% after second injection and gradually reduced with subsequent injections. The most common reason for discontinuation was irregular spotting per vagina (53.9%). Conclusions: Inj. DMPA is a safe, effective, long acting contraceptive taken once in three months. Many women in early reproductive age and lactational period are using inj. DMPA (Anthara) for contraception because of its convenience of dosing and is easily made available at government health care centres free of cost and has no effect on lactation. Discontinuation rate can be reduced by proper counselling.
机译：背景：现在可用的高级避孕装置具有最小的副作用和最大功效。使用安全有效的避孕是在印度时光的需求。 inj。已经发现Depot Medroxy孕酮（DMPA）在哺乳期和中继后患者中提供了有效，长的行为和可逆避孕。本研究的目的是描述妇女使用inj的概况。 DMPA作为避孕，确定其合规性，并评估影响Injuntination的因素。 DMPA（Anthara）在曼迪的政府第三节护理学院。方法：本研究是一项基于记录的18个月（2018年1月至2019年6月）研究。 266名妇女使用妊娠的记录。分析了DMPA作为我们机构的避孕措施。结果：据观察，266名女性48.5％来自21-25岁的年龄组，64.3％是pripara。大多数妇女发起了伤害。 DMPA（Anthara）在泌乳期（56.0％）。最常见的副作用是不规则的出血（54.8％）。第一次注射后停止率为55.6％，第二次注射后16.9％，随后注射逐渐减少。停药最常见的原因是每阴道不规则斑点（53.9％）。结论：手指。 DMPA是一个安全，有效的，长期的避孕药，在三个月内服用一次。早期生殖年龄和泌乳时期的许多女性都使用了Inj。 DMPA（ANTHARA）为避孕，因为它为其提供了便利性，并且在政府保健中心免费提供，并且没有对哺乳期的影响。通过适当的咨询可以减少停机率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号